home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-5,bridge-core-2.1.9,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-20.6,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.1,vc_responsive
Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is now enrolling patients. For this trial, one unique vaccine is designed and manufactured for each patient.
Vaccibody has a collaboration with Nektar Therapeutics and is planning to start testing VB10.NEO in combination with bempegaldesleukin (NKTR-214) in squamous cell carcinoma of head and neck.

Vaccibody’s most advanced program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), evaluating the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3) has published positive 12 months data. Vaccibody has a collaboration with Roche, exploring VB10.16 in combination with their checkpoint inhibitor atezolizumab (Tecentriq®).